Latest news with #NTLA
Business Insider
3 days ago
- Business
- Business Insider
Intellia commercial position in question after safety event. says Goldman
Goldman Sachs believes the grade 4 liver transaminase elevation safety event disclosed by Intellia Therapeutics (NTLA) for the Phase 3 MAGNITUDE study potentially places nex-z's commercial positioning further in question given the CRISPR therapy's lack of an established long-term safety profile. The therapy has shown limited differentiation on efficacy versus siRNA competitors, the analyst tells investors in a research note. Goldman has a Sell rating on Intellia with an $8 price target The stock in morning trading is down 28%, or $2.70, to $6.96. Confident Investing Starts Here:
Business Insider
3 days ago
- Business
- Business Insider
Cantor Fitzgerald Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
In a report released yesterday, Rick Bienkowski from Cantor Fitzgerald reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price target of $65.00. The company's shares closed yesterday at $7.45. Confident Investing Starts Here: Bienkowski covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Legend Biotech, and Verve Therapeutics. According to TipRanks, Bienkowski has an average return of -31.7% and a 6.67% success rate on recommended stocks. In addition to Cantor Fitzgerald, Intellia Therapeutics also received a Buy from JonesTrading's Debanjana Chatterjee in a report issued today. However, yesterday, Goldman Sachs maintained a Sell rating on Intellia Therapeutics (NASDAQ: NTLA). Based on Intellia Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $16.63 million and a GAAP net loss of $114.33 million. In comparison, last year the company earned a revenue of $28.94 million and had a GAAP net loss of $107.44 million
Business Insider
18-05-2025
- Health
- Business Insider
Intellia Therapeutics announces two-year follow-up data from trial of nex-z
Intellia Therapeutics (NTLA) announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran, nex-z, for the treatment of hereditary ATTR amyloidosis with polyneuropathy. Results were shared in an oral presentation on Sunday, May 18 at the 2025 Peripheral Nerve Society, PNS, Annual Meeting in Edinburgh, United Kingdom. The Phase 3 MAGNITUDE-2 trial design of nex-z in ATTRv-PN was also exhibited in a poster presentation. Across patients who received a one-time dose of 0.3 mg/kg or higher, the mean serum TTR reduction by Day 28 was 90%, with levels remaining virtually unchanged for at least 24 months. Favorable trends indicating stability or improvement were observed in patients with ATTRv-PN, including six patients previously on patisiran for a mean of 5.5 years, who had evidence of disease progression prior to entering the study. Stability or improvement was based on evaluation of multiple clinical and biomarker measures, including Neuropathy Impairment Score, modified Neuropathy Impairment Score +7, modified BMI, Norfolk Quality of Life-Diabetic Neuropathy questionnaire and neurofilament light chain
Yahoo
12-04-2025
- Business
- Yahoo
Intellia Focuses on Pipeline Development Amid Stiff Competition
Intellia Therapeutics, Inc. NTLA is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis. Intellia has collaborated with Regeneron Pharmaceuticals REGN for the development of nex-z. Nex-z is part of the company's co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. Two separate phase III studies are evaluating nex-z for treating transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) and hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). The phase III MAGNITUDE study is evaluating the safety and efficacy of nex-z in patients with ATTR-CM. If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for nex-z. The phase III MAGNITUDE 2 study is actively screening patients with ATTRv-PN, with the first patient expected to be dosed shortly. The collaboration with Regeneron for nex-z is a boost for Intellia as it provides the latter with resources to support the development of the candidate. Intellia is developing its wholly owned CRISPR-based pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema ('HAE'). The pivotal phase III HAELO study is actively enrolling patients evaluating NTLA-2002 for treating HAE. Intellia dosed the first patient in the HAELO study in January 2025. Enrollment in the same is likely to be completed in the second half of 2025. The company plans to submit a potential biologics license application for NTLA-2002 in HAE in the second half of 2026. In January 2025, the company announced a strategic reorganization to prioritize its portfolio of late-stage pipeline candidates. As part of the portfolio reorganization, NTLA is planning to prioritize the development of nex-z and NTLA-2002. The company will also reduce its workforce by 27% in 2025. Intellia is gearing up to transition from a late-stage development company to a commercial-ready organization by the end of 2026. The encouraging pipeline progress with nex-z and NTLA-2002 should maintain the momentum for Intellia in 2025. Intellia's pipeline candidates are still in early-to-mid-stage development and some years away from commercialization. Upon successful development and potential approval, the candidates are likely to face stiff competition from companies that are also using the CRISPR/Cas9 gene editing technology to address various diseases in specific areas. The FDA approval of Vertex Pharmaceuticals VRTX and CRISPR Therapeutics' CRSP CRISPR/Cas9 genome-edited cell therapy, Casgevy, for the treatment of sickle cell disease has put the limelight on the gene editing space. The approval for Vertex and CRSP's Casgevy was a breakthrough for medical science, as it was the first for a CRISPR-based gene-editing therapy in the world. VRTX leads the global development and commercialization of Casgevy under the terms of the 2021 agreement, with support from CRISPR Therapeutics. Meanwhile, owing to the latest portfolio reorganization, Intellia has decided to stop the development of its in vivo gene insertion candidate, NTLA-3001, for the treatment of alpha-1 antitrypsin deficiency-associated lung disease. In the absence of a marketed product, the successful development of its pipeline candidates remains a key focus area for Intellia. Failure in the ongoing studies will be a big setback for the company. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Associated Press
04-04-2025
- Business
- Associated Press
NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the 'Class Period'), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Intellia class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants' statements included, among other things, confidence in Intellia's timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Intellia class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Fax: (212) 202-3827
